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Background: Congenital malformations occur in 3-4% of live births. Their prenatal detection is performed by
ultrasound screening. Any announcement about a suspected malformation is a source of stress for the parents, and
misdiagnosis during ultrasound screening can lead to expensive and sometimes iatrogenic medical interventions.
In this study, we aim to determine the false-positive rate, first overall and then by anatomical system, of ultrasound
screening for congenital malformations in the second and third trimesters of pregnancy.
Methods: Our sample includes all children born between 1 January, 2006, and 31 December, 2009, in the French
region of Auvergne, whose mother had a prenatal ultrasound diagnosis of a congenital malformation during the
second or third trimester of pregnancy confirmed by a follow-up ultrasound examination by an expert consultant
ultrasonographer. The study included 526 fetuses, divided in 3 groups: false positives, diagnostic misclassifications, and
true positives. The rates of false positives and diagnostic misclassifications were calculated for the sample as a whole
and then by anatomical system.
Results: Overall, the false-positive rate was 8.8% and the rate of diagnostic misclassification 9.2%. The highest
false-positive rates were found for renal and gastrointestinal tract malformations, and the highest diagnostic
misclassification rates for cerebral and cardiac malformations. The diagnostic misclassification rate was significantly
higher than the false-positive rate for cardiac malformations.
Conclusion: The false-positive rate during prenatal ultrasound is not insignificant; these misdiagnoses cause
psychological stress for the parents and overmedicalisation of the pregnancy and the child.
Keywords: Congenital malformation, Medical practice assessment, Prenatal diagnosis, Pregnancy, Ultrasound screeningBackground
The French national health insurance fund reimburses
three ultrasound examinations during pregnancy, at 11-
13 weeks, 20-24 weeks, and 30-35 weeks, in accordance
with national guidelines [1]. In 2010, there were 802 224
births in metropolitan France [2], from 796 066 deliveries
and thus theoretically 2 388 198 ultrasound examinations.
A national survey in 2010 showed a mean number of
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article, unless otherwise stated.2003 when it was 4.5 ± 2.2 [3]. Congenital malformations,
nonetheless, occur in only 3-4% of live births, as we see
from the registries that monitor the incidence in various
countries, either nationally or regionally. Consequently, an
increasing number of ultrasounds are performed each year
in France, although the number of pregnancies with
anomalies is relatively small and has remained constant.
For these reasons, it becomes important to look at the
false-positive rate to assess our ultrasonographic practices.
Some publications based on these registry data have
looked at the sensitivity of prenatal ultrasound screening
in the general population [4-6], which rose from 41 to
60% during the 1990s and to 80% over the past decade
[7,8]. In the general population, the false-positive rate, allCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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[9-11]. A Spanish hospital-based study found an overall
false-positive rate of 9.3%, regardless of gestational age
[12]. This rate varies according to anatomical system [13].
Accordingly, an Italian study assessed it at 9-11% for sur-
gically curable malformations of the digestive organs and
chest [14]. Other studies have estimated it at 1.5 to 20.0%
in comparing prenatally-identified malformations with
post-mortem examination findings after terminations of
pregnancy [15-24].
To our knowledge, no population-based study has ana-
lysed the false-positive rate by anatomical system and
distinguished it (no malformation detected at birth des-
pite prenatal diagnosis) from the rate of diagnostic mis-
classifications (not all of the malformations suspected
prenatally were confirmed or error about the type of
malformation affecting the organ at birth).
Because most pregnancies are at low risk, any an-
nouncement about a suspected malformation is a source
of stress for the parents [25]. Moreover, any misdiagnosis
can lead to expensive and sometimes iatrogenic medical
interventions. Accordingly, reducing the number of false
positives at anomaly scans as much as possible is essential.
The principal objective of our study was to determine
the false-positive rate during the second and third trimes-
ters of pregnancy in Auvergne, a region of France. Our
secondary objectives were to assess the false-positive rate
by anatomical system and the diagnostic misclassification
rate.
Methods
Auvergne is a rural region in central France, with a popula-
tion estimated on 1 January 2009 at 1 343 964 inhabitants,
that is, 2.2% of the population of metropolitan (European)
France [26]. Auvergne has 10 maternity units (1 level III, 6
level II and 3 level I), coordinated by a perinatal network. It
has only one multidisciplinary prenatal diagnostic centre
(CPDP), which is located in the level III university hospital
centre and works with both the perinatal network and
the Auvergne study centre for congenital malformations
(CEMC-Auvergne). The CPDP’s purpose is to promote ac-
cess to all types of prenatal diagnosis, serve as a clinical and
laboratory reference centre for patients and physicians, and
provide opinions and advice concerning diagnosis, treat-
ment and prognosis to the physicians and clinical patholo-
gists who contact them when they suspect an anomaly in
an embryo or foetus. All fetal ultrasound anomalies identi-
fied throughout the region are presented to the CPDP for
their opinion during a weekly staff meeting, with remote
participation and teleradiology, in accordance with national
guidelines [27].
The CEMC-Auvergne registry is a regional, population-
based registry monitoring malformations in some 13 500
annual births. Terminations of pregnancy are includedregardless of term. Stillbirths are registered at a gestational
age of 22 weeks or more. Live born infants with malforma-
tions are identified up to the age of 1 year through volun-
tary reporting by the region’s hospitals and searches of
medical records of the maternity and paediatric units in
the area. Regardless of the child’s vital status, confirmation
of the malformation (or malformations) is obtained after
birth, by any means (including pathology examination of
foetus or child, in case of death), before it is included in
the CEMC-Auvergne database.
A registry representative participates routinely at these
weekly CPDP expert meetings and was thus able to collect
the names of all the children with a malformation sus-
pected before birth, who were thus “pre-included” in nom-
inative paper records (”pre-inclusion form”). Permanent
inclusion in the registry’s computerised database does not
occur until after birth, following examinations intended to
determine conclusively the presence or absence of the mal-
formation or misclassification about the malformed organ.
The source population of this study comprised chil-
dren whose mother had a prenatal diagnosis of a malfor-
mation after an ultrasound during the second or third
trimester of pregnancy and who were born in Auvergne
between 1 January 2006 and 31 December 2009.
Our sample included all those children whose mother
underwent a follow-up (second-look) ultrasound by a
CPDP ultrasonographer and whose file was considered at a
multidisciplinary CPDP meeting. Live-born or stillborn
children were included if they were delivered in a maternity
unit in Auvergne after 22 completed weeks of gestation
(≥ 22 weeks+0 d). Both the register and our study data-
base include in utero fetal deaths resulting from termi-
nations of pregnancy for fetal anomalies, in accordance
with French law.
The exclusion criteria were the absence of pathology or
other relevant examinations in cases of terminations of
pregnancy or in utero fetal or early neonatal deaths, or the
parents’ refusal to have a work-up that would confirm the
prenatal diagnosis during the baby’s first year of life, or the
impossibility of finding the results of work-ups that were
in fact performed. Our final sample therefore included 526
children (Figure 1).
After birth (or terminations of pregnancy), the children
were divided into three groups: the group of true positives,
that is, those for whom malformations detected prenatally
were confirmed during the postnatal examination; the
group of false positives, that is, the children with a total dis-
cordance (no malformation identified at birth); and the
group of misclassification errors (not all of the malforma-
tions suspected prenatally were confirmed by postnatal
examination or the malformation of the suspected organ
was confirmed at birth but the type of anomaly turned
out to be erroneous). Ventriculomegaly was considered
present if the width of the lateral ventricles, measured
Figure 1 Selection of files for this study.
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Pyelectasis was defined by an anteroposterior diameter of
the renal pelvis > 5 mm between 20-29 weeks and >7 mm
between 30-40 weeks, over several examinations. An ab-
normal quantity of amniotic fluid was defined as either
oligoamnios [amniotic fluid index < 5th percentile] or
polyhydramnios [amniotic fluid index > 95th percentile]
[28]. Intrauterine growth restriction (IUGR) was defined
as a birth weight <3th percentile for gestational age [29]
according to the AUDIPOG (Association des Utilisateurs
de Dossiers Informatisés en Pédiatrie, Obstétrique et
Gynécologie) biometric curves [30].
The false-positive rate has as its numerator the number
of children with a total discordance of one or more mal-
formations identified in utero; its denominator is all 526
children in our study. The rate of misclassification errors
was calculated as the ratio of the number of children with
a partial discordance, again to all children in the study. To
calculate the rates by anatomical system, only the files in-
volving at least one malformation of the system consid-
ered were included, regardless of the number of systems
with anomalies. Thus the files involving several systems
were counted several times.
A Chi-2 test or Fisher’s exact test, as appropriate, was
performed for the categorical variables. Analysis of vari-
ance (ANOVA) was used for the continuous variables.
The level of statistical significance was set at 0.05. SAS
software (version 9.1, SAS, Inc, Cary, NC, 2002-2003)
was used to perform the analyses.Results
The final analysis included files for 526 children, prenatally
diagnosed with 828 malformations. Malformations were
diagnosed in 339 of these files during the second trimester
and in 187 during the third (Figure 1).
Within this cohort, the mean maternal age was 29.4
(± 5.6) years. More than half (55.2%) had at least some
university-level education. Smoking during the first tri-
mester of pregnancy was noted for 28.5%. Maternal body
mass index (BMI) ≥25 was reported for 11.6%. A degree of
consanguinity with the spouse existed for 2.3% (Table 1).
A history of familial congenital malformations was re-
ported for 20.6% (Table 2). The mean number of previous
pregnancies was 1.3 (+/- 1.5), and the rate of previous
terminations 1.7%. The quantity of amniotic fluid was
abnormal in 14.3% of the pregnancies (Table 2).
Induced abortion occurred in 23.1% of the cases, and
71.7% of the children were live born (Table 3). The mean
gestational age at the prenatal malformation diagnosis
was 26.9 weeks (+/- 4.9). Each child had a mean of
2.1 (+/- 1.8) malformations in 1.5 (+/-1.1) anatomical
systems (Table 4).
Tables 1 to 4 summarise the social, demographic, med-
ical, obstetric and ultrasonographic data of mothers and
children. There was no difference between the three
groups for mothers’ characteristics, except for maternal
obesity, which was more frequent in the true-positive
group (p = 0.02) (Table 1). Previous spontaneous abortions
were more often reported in the misclassification group
Table 1 Social and demographic data
Total cohort
(n = 526) %
False positives
(n = 39) %
Misclassification
(n = 49) %
True positive
(n = 438) %
p1
Maternal age (n = 526) (n = 39) (n = 49) (n = 435)
<25 years 18.1 19.2 22.5 17.5 0.62
25-34 years 62.3 65.9 59.2 62.3
≥35 years 19.6 15.9 18.4 20.2
Educational level (n = 279) (n = 22) (n = 25) (n = 232)
Primary and middle school 24.6 20.8 20.0 25.4 0.81
High school 20.3 16.7 16.0 21.1
Post-secondary 55.2 62.5 64.0 53.5
Smoking (n = 482) (n = 40) (n = 43) (n = 399)
28.5 32.6 20.9 28.8 0.45
BMI2 ≥ 25 (n = 526) (n = 39) (n = 49) (n = 438)
11.6 8.5 0 13.2 0.02
Consanguinity (n = 526) (n = 39) (n = 49) (n = 438)
2.3 6.5 0 2.1 0.08
1Comparison of 3 groups: False positives, Misclassifications, True positives; 2BMI (Body Mass Index).
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Terminations of pregnancy after 22 weeks were reported
more often in the misclassification group (p = 0.0001).
Gestational age at birth was higher in the group of false
positives (p = 0.001). Weight and height at birth were also
higher in the false-positive group, compared with the two
other groups (p = 0.001). Finally, intrauterine growth re-
striction (IUGR) was more frequent in the misclassifica-
tion group (p = 0.03) (Table 3). There were more isolated
malformations in the false-positive group and more mul-
tiple malformations (≥4) in the diagnostic misclassification
group (p = 0.0001). Moreover, in general, only one organ
was affected in the false-positive group, and several ana-
tomical systems were involved in the misclassification
group (p = 0.0001) (Table 4).
Among the 526 children, the false-positive rate was
8.8% (95% CI: 6.5-11.5) after the specialized follow-up
ultrasound, regardless of the term at ultrasound. The
false-positive rate was 7.9% (95% CI: 5.3-11.3) when the
malformation was screened during the second trimester
and the specialized follow-up ultrasound performed be-
tween 20 and 30 weeks, and 10.4% (95% CI: 6.5-15.6) when
the malformation was screened during the third trimester
and the specialized follow-up ultrasound performed after
30 weeks.
The overall diagnostic misclassification rate was 9.2%
(95% CI: 6.9-11.9); when the malformation was screened
during the second trimester and the specialized follow-
up ultrasound performed between 20-30 weeks, it was
10.8% (95% CI: 7.7-14.6), and when screening took place
during the third trimester and the specialized follow-up
ultrasound after 30 weeks, 6.3% (95% CI: 3.3-10.7).Table 5 presents the rates of false positives and diagnos-
tic misclassifications according to the affected anatomical
system. Only the cardiovascular system showed a signifi-
cant difference between the false-positive group and the
diagnostic misclassification group, with a higher propor-
tion of cardiac malformations in the latter (p = 0.01).
Discussion
This study reports false-positive and diagnostic misclassifi-
cation rates during ultrasound screening in the general
population over a 4-year period. The false-positive rate in
this study (8.8%) is similar to that in recent data from the
literature, with rates between 9 and 12% [9,12,22,31]. The
oldest studies reported higher rates (up to 33%) [10]. This
rate therefore varies according to the study period: as pre-
natal diagnosis has improved with time, the false-positive
rate has become lower in the most recent studies and is
now consistent with our rate.
The rate of diagnostic misclassifications in our study
(9.2%) seems higher than those found in the literature,
which are around 3% [19-21]. This discordance may be
explained by our study’s coverage of two trimesters of
pregnancy; the literature appears to consider only the sec-
ond trimester (12-28 weeks) [15-24]. Moreover, the series
in the literature concern only cases of induced abortions
for severe malformations, which are most often well iden-
tified. We note that the cases with terminations in the
misclassification group in our study had all multiple
anomalies and that the incorrectly diagnosed malforma-
tions would not have influenced medical decision. The ob-
jective of this paper was to describe the global rate of false
positives, that is, all diagnoses of malformations that
Table 2 Medical and obstetric data
Total cohort False positives Misclassification True positive P6
(n = 526) (n = 39) (n = 49) (n = 438)
% [m ± SD] % [m ± SD] % [m ± SD] % [m ± SD]
Number of pregnancies1 (n = 526) (n = 39) (n = 49) (n = 438)
[1.3 ± 1.5] [1.1 ± 1.3] [1.7 ± 1.8] [1.3 ± 1.5] 0.38
Miscarriages (n = 518) (n = 39) (n = 49) (n = 430)
9.6 17.1 34.7 18.1 0.02
Elective termination (n = 519) (n = 39) (n = 49) (n = 431)
12.9 6.4 16.3 13.2 0.31
TOPFA2 (n = 517) (n = 39) (n = 49) (n = 429)
1.7 4.3 2.0 1.4 0.16
Nulliparous (n = 524) (n = 39) (n = 49) (n = 436)
48.1 46.8 44.9 48.6 0.44
Maternal diseases3 (n = 520) (n = 39) (n = 49) (n = 432)
Diabetes 5.3 6.4 4.1 6.3 0.87
Epilepsy 0.9 0 0 1.2 0.37
Hypertension 0.8 2.1 0 0.7 0.35
Familial malformations (n = 525) (n = 39) (n = 49) (n = 437)
Similar malformation 6.9 0 6.1 7.8 0.11
Different malformation 14.6 8.5 10.2 15.8 0.27
Multiple pregnancy (n = 526) (n = 39) (n = 49) (n = 438)
3.4 0 8.2 3.2 0.08
ART4 (n = 520) (n = 38) (n = 46) (n = 436)
6.1 2.2 8.7 6.2 0.68
PRD5 (n = 508) (n = 38) (n = 47) (n = 423) 0.64
33.1 28.3 29.3 34.0 0.64
Amniotic fluid anomaly (n = 516) (n = 39) (n = 49) (n = 428)
Oligoamnios 7.7 0 18.4 7.5 0.01
Hydramnios 6.6 2.1 8.2 6.8
1Number of pregnancies, mean. 2 TOPFA (Termination Of Pregnancy for Fetal Anomaly):In France, when a termination of pregnancy is envisaged for the reason
that there is a strong probability that the child has a particularly severe condition recognized as incurable at the time of diagnosis, a multidisciplinary team from
the authorised antenatal diagnostic center is responsible for examining the woman’s request and issuing an advisory opinion. If at the conclusion of this team’s
assessment, two physicians consider that there is a strong probability that the child has such a condition, they complete a written attestation, one copy of which
is provided to the woman. 3Maternal chronic disease (preceding the pregnancy) 4ART (Assisted Reproductive Technologies) 5PRD (Pregnancy related diseases
including pregnancy related diabetes or hypertension, preeclampsia, etc.) 6Comparison of 3 groups: False positives, misclassifications, True positives.
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the false positive diagnoses in the misclassification group
may wrongly evoke suspected syndromes. Thus while they
may not influence the medical outcome of the pregnancy,
they may nonetheless induce specific unnecessary comple-
mentary examinations, be a source of stress and have costs
for society.
These rates are based on data from one regional pre-
natal diagnosis centre, where all pregnancies with sus-
pected foetal malformations are assessed, contrary to
published studies that compare several hospitals of dif-
ferent levels [9,22].
Somewhat surprisingly, the proportion of women with a
BMI ≥ 25 was higher in the true-positive group than inthe other two groups. This result is discordant with that of
the FASTER trial, which showed an inverse relation be-
tween maternal BMI and the false-negative rate [32]. This
overrepresentation of overweight women in the group of
true positives might be related to their overrepresentation
in the group with malformed children, because of the
teratogenic effect of some maternal diseases found more
frequently in this population (especially diabetes). It is im-
possible to study the predictive factors for false positive or
misclassified diagnoses because our database includes only
the children with a prenatal diagnosis of malformation;
the medical, social and demographic characteristics of the
pregnancies studied might thus be different from those of
pregnancies with no anomalies.
Table 3 Obstetric and neonatal outcome
Total cohort False positives Misclassification True positives p1
(n = 526) (n = 39) (n = 49) (n = 438)
% [m ± SD] % [m ± SD] % [m ± SD] % [m ± SD]
Year of birth (n = 526) (n = 39) (n = 49) (n = 438)
2006 22.5 17.0 26.6 22.5 0.49
2007 25.1 21.3 20.4 26.0
2008 28.1 34.0 28.6 27.4
2009 24.3 27.7 24.5 23.9
Female (n = 526) 45.9 (n = 39) 44.7 (n = 49) 48.9 (n = 438) 45.7 0.89
Pregnancy outcome2 (n = 526) (n = 39) (n = 49) (n = 438)
TOPFA< 21 weeks 2.3 0 4.2 2.3 0.39
TOPFA ≥ 22 weeks 20.8 0 31.3 21.9 0.0001
In utero fetal death 2.5 0 2.1 2.7 0.50
Neonatal death 2.7 2.1 2.1 2.7 0.94
Term at birth (weeks) (n = 526) (n = 39) (n = 49) (n = 438)
[35.5 ± 6.1] [39.4 ± 1.9] [34.2 ± 6.5] [35.2 ± 6.2] 0.001
Weight (g) (n = 526) (n = 39) (n = 49) (n = 438)
[2588 ± 1134] [3272 ± 525] [2265 ± 1211] [2551 ± 1147] 0.001
IUGR (3rd Percentile) (n = 482) (n = 39) (n = 44) (n = 399)
4.9 2.1 9.1 4.8 0.03
Height (cm) (n = 526) (n = 39) (n = 49) (n = 438)
[45.1 ± 7.7] [49.3 ± 2.1] [42.2 ±8.9] [44.9 ±7.8] 0.001
Type of malformation (n = 526) (n = 39) (n = 49) (n = 438)
Single 76.0 100 53.1 76.3 0.40
Multiple 8.2 0 22.5 7.3
Syndrome with normal karyotype 4.3 0 8.2 4.3
Chromosomal anomalies 11.4 0 16.3 12.1
1Comparison of 3 groups: False positives, Misclassifications, True positives.
2TOPFA (Termination Of Pregnancy for Fetal Anomaly).
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were isolated, as previously reported in the literature [12].
They thus differ from the diagnostic misclassification cat-
egory, where there are more often multiple malformations
involving several anatomical systems. This characteristic is
also present in studies of correlations between prenatal data
and autopsy diagnoses, where most of the fetuses have mul-
tiple malformations, which can induce some difficulties in
interpreting the ultrasonographic images [10,22]. It has
already been reported that the value of ultrasound is limited
in situations with multiple malformations [23,33]. Comple-
mentary imaging by nuclear magnetic resonance (NMR)
appears more effective in some cases [33]. As a conse-
quence, terminations of pregnancy were more frequent in
the misclassification group as the overall malformations
were more severe than in the other two groups. No termin-
ation of pregnancy was performed for any of the malforma-
tions in the false-positive group, for none of them suggestedthat “there was a strong probability that the child to be born
would have a severe condition recognized as incurable at
diagnosis,” the criterion for termination under French law.
Oligohydramnios was also present more often in the
misclassification group; as already reported, oligohydram-
nios may lead to inconclusive ultrasonographic diagnoses
[34]. Finally, IUGR affected more children in the misclassi-
fication group; it has previously been demonstrated that
risk of IUGR is frequently associated with a high number
of malformations [35].
The study of the false-positive rate by anatomical sys-
tem shows that these were most often gastrointestinal
tract and kidney malformations. These results are
equivalent to those in the Eurofetus study, where anom-
alies of the urinary tract and gastrointestinal system
respectively accounted for 16.5% and 15.2% of the false-
positive diagnoses [9] and in the Spanish hospital-based
study, where urinary tract anomalies had the highest
Table 4 Characteristics of malformations
Total cohort False positive Misclassification True positive p1
(n = 526) (n = 39) (n = 49) (n = 438)
% [m ± SD] % [m ± SD] % [m ± SD] % [m ± SD]
Term at prenatal diagnosis or malformation (weeks): (n = 526) [26.9 ± 4.9] (n = 39) [27.2 ± 5.2] (n = 49) [26.1 ± 4.8] (n = 438) [26.9 ± 4.9] 0.45
20-25 50.9 46.8 58.6 50.0 0.92
26-29 13.1 10.6 20.7 13.5
30-35 32.4 38.3 20.7 33.1
>35 3.6 4.3 0 3.4
Number of malformations (n = 526) (n = 39) (n = 49) (n = 438)
1 51.7 93.6 6.1 52.3 0.0001
2 21.9 4.3 32.7 22.6
3 13.7 2.1 22.5 13.9
≥ 4 12.7 0 38.8 11.2
Number of anatomical systems affected (n = 526) (n = 39) (n = 49) (n = 438)
1 71.9 100 48.9 71.9 0.0001
2 13.5 0 20.4 13.9
3 6.7 0 6.1 7.3
≥ 4 7.9 0 24.5 6.9
1Comparison of 3 groups: False positives, Misclassifications, True positives.
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gastrointestinal system had one of the highest false-
positive rates (11.6%) [12].
It has now been demonstrated that the course of pyelec-
tasis depends on its size [36]. Dilatation measured at
15 mm prenatally during the third trimester appears to be
the threshold value for suspecting the presence of renal
dysplasia or an underlying uropathy at birth. For dilatation
of 10 mm, spontaneous resolution is observed in nearly
35% of cases, and for dilatation less than 10 mm, resorp-
tion occurs in nearly 50% to 80% of cases [37,38]. In ourTable 5 Rates of false positives and diagnostic misclassificatio
Malformations identified in utero
Bone malformations (n = 56)
Cardiac malformations1 (n = 86)
Cerebral malformations2 (n = 98)
Malformations of the respiratory system and intrathoracic organs (n = 16)
Craniofacial malformations (n = 45)
Malformations of the eyes (n = 4)
Malformations anterior abdominal wall (n = 14)
Malformations of genital organs (n = 35)
Renal malformations 3(n = 169)
Malformations of the gastrointestinal tract (n = 41)
1The specific cardiac anomaly most often misdiagnosed was ventricular septal defe
2The specific cerebral anomalies most often misdiagnosed were anomaly of the cor
3The specific renal anomaly most overdiagnosed in the false-positive group was ren
4Comparison between 2 groups: False positives, Misclassification.study of the 15 prenatal cases of isolated pyelectasis not
observed after birth, 12 had a renal pelvis smaller than
10 mm. However, pyelectasis can disappear because of
newborn dehydration at birth and be detected at a later
check-up. Infants in our study were followed up to one
year of age and thus received the maximum duration of
postnatal renal monitoring.
Data about diagnostic misclassifications are sparse; they
are grouped most often in the literature with the false po-
sitives [19,21,23]. Studies of the correlation between pre-
natal ultrasound scans and pathology examinations showns by anatomical system (number of files)
False positives Misclassification p4
% (95% CI) % (95% CI)
3.6 (0.04-12.3) 12.5 (5.2-24.1) 0.10
3.4 (0.07-9.5) 14.6 (8.0-23.7) 0.01
7.1 (4.2-16.4) 15.3 (8.7-23.5) 0.22
6.3 (1.5-36.4) 0 0.16
4.4 (5.4-15.1) 15.6 (6.5-29.5) 0.09
0 25 (0-67.4) 0.31
7.1 (0-20.6) 21.4 (4.6-50.8) 0.32
5.7 (2.4-28.1) 7.9 (1.7-21.4) 0.48
11.8 (7.4-17.7) 13.6 (8.8-19.7) 0.65
12.2 (4.1-26.2) 9.8 (2.7-23.1) 0.73
ct (n = 5).
pus callosum (n = 5) and ventriculomegaly (n = 5).
al pyelectasis (n = 15).
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disease [18,19,21], with the most frequent diagnostic error
that of a ventricular septal defect, which often marks
valvular disease [19,39]. Similarly, it has already been
shown that postnatal pathology examinations fail to con-
firm a substantial portion of cerebral malformations [23].
Moreover, moderate ventriculomegaly (with a size be-
tween 10 and 15 mm) may be a type of functional anomaly
that sometimes regresses during pregnancy [40,41]. The
ventricle size of the cases of isolated prenatal ventriculo-
megaly not confirmed after birth in our study ranged from
10 to 13 mm. It has been demonstrated that early cerebral
autolysis can also mask the presence of an anomaly during
the postnatal period and prevent diagnostic confirmation
of the prenatal imaging [23].
Corpus callosum agenesis is the most frequent commis-
sural malformation. The false-positive rate of ultrasound
screening for this malformation varies from 0 to 22%. It
may be over-diagnosed because of its association with ven-
triculomegaly, which may hinder adequate visualization of
the cerebral structures [42]. Three-dimensional sonog-
raphy makes it possible to acquire the foetal head volume
from the axial view and then, by reconstructing the image
with the multiplanar technique, to obtain a suitable view
of the corpus callosum without the technical difficulties of
2D-sonography. Second-step complementary NMR re-
mains, however, a clinically valuable adjunct to ultrasound
and provides additional information when the ultrasound
diagnosis is uncertain [43,44].
One limitation of our study is that the CEMC data-
base registers only children in whom malformations
have been confirmed after birth or induced abortion, so
that it is not possible to analyse the predictive values of
the ultrasound screening. Another limitation may be
the absence in our database of reliable data about the
mode of dating pregnancies: this information is missing
for many women. Nonetheless, in France the national
health insurance fund reimburses three ultrasound ex-
aminations during pregnancy; the first is performed be-
tween 11 and 14 weeks to determine term and measure
nuchal thickness as part of trisomy 21 screening. Ac-
cordingly, the pregnancy date is most often determined
by fetal ultrasound. The national survey perinatal found
that only 0.1% of women had no ultrasound during
pregnancy in 2003, and 0.2% in 2010 [45]. It is therefore
unlikely that our results are biased (as ultrasonographic
term is correlated with the beginning of pregnancy) by
the absence of data about early fetal ultrasound.
Conclusion
The prenatal ultrasound false-positive rate in the region of
Auvergne during the second and third trimesters was 8.8%.
This rate varied according to the anatomical system. These
erroneous diagnoses have psychological repercussions forfamilies and also engender costs for society, due to the
futile medical examinations. Continuation of this work
should seek to identify the factors that promote false-
positive prenatal ultrasound findings.
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